Each cardiac muscle cell can have over 5,000 sarcomeres, which compounds both the shortening and relaxation events. "This process appears to be regulated by myosin-binding protein-C (cMyBP-C), which ...

In a recent study published in Nature Communication, researchers employed artificial intelligence (AI)-driven virtual screening to discover 'F10', a novel cardiac-specific myosin inhibitor for ...

No one can live without a heart pumping blood to the rest of the body. New research from the University of Missouri School of Medicine reveals more information about this vital function and how it’s ...

Atrial fibrillation, heart failure and stroke – hypertrophic cardiomyopathy can lead to many serious health conditions and is a major cause of sudden cardiac death in people younger than 35. „The ...

Credit: Getty Images HCM is a genetic disease, usually caused by mutations in sarcomere proteins such as myosin, actin, tropomyosin, and myosin-binding protein C. Hypertrophic cardiomyopathy (HCM) ...

Tenaya Therapeutics reports positive preclinical data for TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, published in Nature Communications. Tenaya Therapeutics, Inc. has ...

Tenaya Therapeutics, Inc. announced that it will present new data on its MYBPC3-associated hypertrophic cardiomyopathy (HCM) program at the American College of Cardiology's Annual Scientific Session ...

Please provide your email address to receive an email when new articles are posted on . A first-in-human phase 1 trial is testing a novel gene therapy for hypertrophic cardiomyopathy. The one-time ...

The human heart, often described as the body's engine, is a remarkable organ that tirelessly beats to keep us alive. At the core of this vital organ, intricate processes occur when it contracts, where ...